37.91 USD
-0.22 (-0.58%)
37.91 USD
0 (0%)
HRMY gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. HRMY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. HRMY is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make HRMY suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
HRMY had positive earnings in the past year.
In the past year HRMY had a positive cash flow from operations.
HRMY had positive earnings in 4 of the past 5 years.
Of the past 5 years HRMY 4 years had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 15.37%, HRMY belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
HRMY's Return On Equity of 22.23% is amongst the best of the industry. HRMY outperforms 92.67% of its industry peers.
With an excellent Return On Invested Capital value of 17.20%, HRMY belongs to the best of the industry, outperforming 94.76% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for HRMY is significantly above the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROIC | 17.2% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
HRMY has a Profit Margin of 22.48%. This is amongst the best in the industry. HRMY outperforms 91.62% of its industry peers.
HRMY's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 27.32%, HRMY belongs to the best of the industry, outperforming 93.19% of the companies in the same industry.
HRMY's Operating Margin has declined in the last couple of years.
HRMY has a better Gross Margin (77.70%) than 83.25% of its industry peers.
In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for HRMY has been increased compared to 1 year ago.
The number of shares outstanding for HRMY has been reduced compared to 5 years ago.
The debt/assets ratio for HRMY has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.60 indicates that HRMY is not in any danger for bankruptcy at the moment.
The Altman-Z score of HRMY (5.60) is better than 74.87% of its industry peers.
HRMY has a debt to FCF ratio of 0.57. This is a very positive value and a sign of high solvency as it would only need 0.57 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.57, HRMY belongs to the best of the industry, outperforming 96.86% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that HRMY is not too dependend on debt financing.
The Debt to Equity ratio of HRMY (0.18) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Altman-Z | 5.6 |
ROIC/WACC1.82
WACC9.46%
2.3 Liquidity
HRMY has a Current Ratio of 3.75. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.75, HRMY perfoms like the industry average, outperforming 57.59% of the companies in the same industry.
A Quick Ratio of 3.72 indicates that HRMY has no problem at all paying its short term obligations.
HRMY's Quick ratio of 3.72 is in line compared to the rest of the industry. HRMY outperforms 58.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
HRMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.71%, which is quite impressive.
Measured over the past years, HRMY shows a very strong growth in Earnings Per Share. The EPS has been growing by 44.61% on average per year.
The Revenue has grown by 21.13% in the past year. This is a very strong growth!
HRMY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.13% yearly.
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
3.2 Future
HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.10% yearly.
The Revenue is expected to grow by 14.64% on average over the next years. This is quite good.
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.64%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.92, which indicates a very decent valuation of HRMY.
Compared to the rest of the industry, the Price/Earnings ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 88.48% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.84, HRMY is valued rather cheaply.
With a Price/Forward Earnings ratio of 8.97, the valuation of HRMY can be described as very reasonable.
89.53% of the companies in the same industry are more expensive than HRMY, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.40. HRMY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.92 | ||
| Fwd PE | 8.97 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 96.34% of the companies listed in the same industry.
HRMY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HRMY is cheaper than 95.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.35 | ||
| EV/EBITDA | 6.68 |
4.3 Compensation for Growth
HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HRMY has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HRMY's earnings are expected to grow with 25.00% in the coming years.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y29.75%
EPS Next 3Y25%
5. Dividend
5.1 Amount
No dividends for HRMY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
37.91
-0.22 (-0.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners85.21%
Inst Owner Change-7.63%
Ins Owners1.64%
Ins Owner Change-61.8%
Market Cap2.18B
Revenue(TTM)825.94M
Net Income(TTM)185.68M
Analysts78.82
Price Target47.11 (24.27%)
Short Float %9.04%
Short Ratio5.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)1.4%
PT rev (3m)-8.8%
EPS NQ rev (1m)-1.9%
EPS NQ rev (3m)-5.87%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)2.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)2.01%
Revenue NY rev (3m)2.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.92 | ||
| Fwd PE | 8.97 | ||
| P/S | 2.64 | ||
| P/FCF | 7.35 | ||
| P/OCF | 7.34 | ||
| P/B | 2.61 | ||
| P/tB | 2.95 | ||
| EV/EBITDA | 6.68 |
EPS(TTM)3.18
EY8.39%
EPS(NY)4.23
Fwd EY11.15%
FCF(TTM)5.15
FCFY13.6%
OCF(TTM)5.17
OCFY13.63%
SpS14.34
BVpS14.5
TBVpS12.84
PEG (NY)0.4
PEG (5Y)N/A
Graham Number32.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROCE | 22.91% | ||
| ROIC | 17.2% | ||
| ROICexc | 54.26% | ||
| ROICexgc | 78.12% | ||
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% | ||
| FCFM | 35.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 3% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 14.73 | ||
| Cash Conversion | 119.28% | ||
| Profit Quality | 159.9% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z | 5.6 |
F-Score6
WACC9.46%
ROIC/WACC1.82
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.64%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year37.1%
EBIT Next 3Y27.64%
EBIT Next 5Y22.34%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a fundamental rating of 8 / 10 to HRMY.
Can you provide the valuation status for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.
Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.
What is the valuation of HARMONY BIOSCIENCES HOLDINGS based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 11.92 and the Price/Book (PB) ratio is 2.61.